Objective To investigate the clinical efficacy of immune enhanced enteral nutrition in patients with septic tumor. Methods From June 2018 to July 2020, the patients with sepsis in the intensive care unit of Chongqing Dazu District People′s Hospital were randomly divided into experimental group (n=30) and control group (n=30). The control group was given conventional nutrition treatment, and the experimental group was given immune enhanced compound enteral nutrition preparation on the basis of the control group. We also monitored and compared the serum albumin (ALB), calcitonin (PCT), C reactive protein (CRP), sequential organ failure assessment score (SOFA), D⁃lactate (D⁃Lac), diamine oxidase (DAO) and bacterial endotoxin in three groups of patients at three time points (0 weeks, 1 weeks, 2 weeks), and monitored intestinal function indexes of two groups of patients with intestinal dysfunction (diarrhea, abdominal distention, gastric retention). Pulmonary infection, ICU stay time and death cases. Results There were no significant differences in ALB, PCT, CRP, SOFA score, the number of cases of pulmonary infection, ICU stay time and death cases, and survival curve between the two groups (P>0.05). The indexes of intestinal function (DAO, D⁃Lac, endotoxin) in the experimental group decreased more significantly than those in the control group (P<0.05). The number of bowel dysfunction (diarrhea, abdominal distention, gastric retention) in the control group was more than that in the experimental group, with significant difference (P<0.05).Conclusion Early enteral nutrition therapy can improve the nutritional and inflammatory state of tumor patients with sepsis, and improve the therapeutic effect of tumor patients. Immune enhanced compound enteral nutrition therapy can improve the intestinal mucosal barrier function of tumor patients, and reduce the occurrence of intestinal dysfunction complications to a certain extent.